Differential anti-diabetic effects and mechanism of action of charantin-rich extract of Taiwanese Momordica charantia between type 1 and type 2 diabetic mice

Food and Chemical Toxicology

Volumn 69, Issue , 2014, Pages 347-356

  Wang, Hsien Yi ^a,b   Kan, Wei Chih ^a,c   Cheng, Tain Junn ^a,b,d   Yu, Sung Hsun ^e   Chang, Liang Hao ^e   Chuu, Jiunn Jye ^e  

^a CHI MEI MEDICAL CENTER   (Taiwan)

^b CHIA NAN UNIVERSITY OF PHARMACY AND SCIENCE   (Taiwan)

^c CHUNG HUA UNIVERSITY   (Taiwan)

^d NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^e SOUTHERN TAIWAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Taiwan)

Author keywords

Charantin; Hypoglycemic; Insulin signaling; Momordica charantia; Pancreatic cells; Type 2 diabetes

Indexed keywords

CHARANTIN; GLUCOSE; GLUCOSE TRANSPORTER 4; INSULIN; MOMORDICA CHARANTIA EXTRACT; STREPTOZOCIN; TOLBUTAMIDE; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; INSULIN RECEPTOR SUBSTRATE; IRS1 PROTEIN, MOUSE; PLANT EXTRACT; SLC2A4 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDIABETIC ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG MECHANISM; GLUCOSE INTOLERANCE; IN VITRO STUDY; INSULIN BLOOD LEVEL; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID DIET; MALE; MOMORDICA CHARANTIA; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET BETA CELL; PROTEIN EXPRESSION; SKELETAL MUSCLE; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; ANIMAL; BLOOD; BODY WEIGHT; CHEMISTRY; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; INBRED MOUSE STRAIN; INSTITUTE FOR CANCER RESEARCH MOUSE; METABOLISM; PATHOLOGY;

ANIMALS; BLOOD GLUCOSE; BODY WEIGHT; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; GLUCOSE TOLERANCE TEST; GLUCOSE TRANSPORTER TYPE 4; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RECEPTOR SUBSTRATE PROTEINS; MALE; MICE, INBRED ICR; MICE, INBRED STRAINS; MOMORDICA CHARANTIA; PLANT EXTRACTS;

EID: 84901416409     PISSN: 02786915     EISSN: 18736351     Source Type: Journal    
DOI: 10.1016/j.fct.2014.04.008     Document Type: Article

References (53)

1. Ahmed I., Lakhani M.S., Gillett M., John A., Raza H. Hypotriglyceridemic and hypocholesterolemic effects of anti-diabetic Momordica charantia (karela) fruit extract in streptozotocin-induced diabetic rats. Diabetes Res. Clin. Pract. 2001, 51:155-161.
2. Carr M.C., Brunzell J.D. Abdominal obesity and dyslipidemia in the metabolic syndrome: importance of type 2 diabetes and familial combined hyperlipidemia in coronary artery disease risk. J. Clin. Endocrinol. Metab. 2004, 89:2601-2607.
3. Chen Q., Chan L.L., Li E.T. Bitter melon (Momordica charantia) reduces adiposity, lowers serum insulin and normalizes glucose tolerance in rats fed a high fat diet. J. Nutr. 2003, 133:1088-1093.
4. Dans A.M., Villarruz M.V., Jimeno C.A., Javelosa M.A., Chua J., Bautista R., Velez G.G. The effect of Momordica charantia capsule preparation on glycemic control in type 2 diabetes mellitus needs further studies. J. Clin. Epidemiol. 2007, 60:554-559.
5. Dekel Y., Glucksam Y., Elron-Gross I., Margalit R. Insights into modeling streptozotocin-induced diabetes in ICR mice. Lab. Anim. (NY) 2009, 38:55-60.
6. Doyle M.E., Egan J.M. Pharmacological agents that directly modulate insulin secretion. Pharmacol. Rev. 2003, 55:105-131.
7. Fernandes N.P., Lagishetty C.V., Panda V.S., Naik S.R. An experimental evaluation of the antidiabetic and antilipidemic properties of a standardized Momordica charantia fruit extract. BMC Complement Altern. Med. 2007, 24(7):29.
8. Grover J.K., Rathi S.S., Vats V. Amelioration of experimental diabetic neuropathy and gastropathy in rats following oral administration of plant (Eugenia jambolana, Mucuna pruriens and Tinospora cordifolia) extracts. Indian J. Exp. Biol. 2002, 40:273-276.
9. Hafizur R.M., Kabir N., Chishti S. Modulation of pancreatic β-cells in neonatally streptozotocin-induced type 2 diabetic rats by the ethanolic extract of Momordica charantia fruit pulp. Nat. Prod. Res. 2001, 25(4):353-367.
10. Han C., Hui Q., Wang Y. Hypoglycaemic activity of saponin fraction extracted from Momordica charantia in PEG/salt aqueous two-phase systems. Nat. Prod. Res. 2008, 22:1112-1119.
11. Harinantenaina L., Tanaka M., Takaoka S., Oda M., Mogami O., Uchida M., Asakawa Y. Momordica charantia constituents and antidiabetic screening of the isolated major compounds. Chem. Pharm. Bull. (Tokyo) 2006, 54:1017-1021.
12. Hazarika R., Parida P., Neog B., Yadav R.N. Binding Energy calculation of GSK-3 protein of Human against some anti-diabetic compounds of Momordica charantia Linn (Bitter melon). Bioinformation 2012, 8:251-254.
13. Higashida K., Higuchi M., Terada S. Dissociation between PGC-1alpha and GLUT-4 expression in skeletal muscle of rats fed a high-fat diet. J. Nutr. Sci. Vitaminol. (Tokyo) 2009, 55:486-491.
14. Homs J., Ariza L., Pages G., Verdu E., Casals L., Udina E., Chillon M., Bosch A., Navarro X. Comparative study of peripheral neuropathy and nerve regeneration in NOD and ICR diabetic mice. J. Peripher. Nerv. Syst. 2011, 16:213-227.
15. Jayasooriya A.P., Sakono M., Yukizaki C., Kawano M., Yamamoto K., Fukuda N. Effects of Momordica charantia powder on serum glucose levels and various lipid parameters in rats fed with cholesterol-free and cholesterol-enriched diets. J. Ethnopharmacol. 2000, 72:331-336.
16. Josefsen K., Nielsen M.D., Jorgensen K.H., Bock T., Norremolle A., Sorensen S.A., Naver B., Hasholt L. Impaired glucose tolerance in the R6/1 transgenic mouse model of Huntington's disease. J. Neuroendocrinol. 2008, 20:165-172.
17. Kahn S.E. The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes. Diabetologia 2003, 46:3-19.
18. Kar A., Choudhary B.K., Bandyopadhyay N.G. Comparative evaluation of hypoglycaemic activity of some Indian medicinal plants in alloxan diabetic rats. J. Ethnopharmacol. 2003, 84:105-108.
19. Keller A.C., Ma J., Kavalier A., He K., Brillantes A.M., Kennelly E.J. Saponins from the traditional medicinal plant Momordica charantia stimulate insulin secretion in vitro. Phytomedicine 2011, 19:32-37.
20. King H., Aubert R.E., Herman W.H. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 1998, 21:1414-1431.
21. Klomann S.D., Mueller A.S., Pallauf J., Krawinkel M.B. Antidiabetic effects of bitter gourd extracts in insulin-resistant db/db mice. Br. J. Nutr. 2010, 104:1613-1620.
22. Kumar R., Balaji S., Uma T.S., Sehgal P.K. Fruit extracts of Momordica charantia potentiate glucose uptake and up-regulate Glut-4, PPAR gamma and PI3K. J. Ethnopharmacol. 2009, 126:533-537.
23. Lane J.T. Animal model of human maturity onset diabetes of the young-type 2: similar but different?. Transl. Res. 2011, 157:109-110.
24. Matias I., Gonthier M.P., Petrosino S., Docimo L., Capasso R., Hoareau L., Monteleone P., Roche R., Izzo A.A., Di Marzo V. Role and regulation of acylethanolamides in energy balance. Focus on adipocytes and beta-cells. Br. J. Pharmacol. 2007, 152:676-690.
25. Miura T., Suzuki W., Ishihara E., Arai I., Ishida H., Seino Y., Tanigawa K. Impairment of insulin-stimulated GLUT4 translocation in skeletal muscle and adipose tissue in the Tsumura Suzuki obese diabetic mouse: a new genetic animal model of type 2 diabetes. Eur. J. Endocrinol. 2001, 145:785-790.
26. Miura T., Itoh Y., Iwamoto N., Kato M., Ishida T. Suppressive activity of the fruit of Momordica charantia with exercise on blood glucose in type 2 diabetic mice. Biol. Pharm. Bull. 2004, 27:248-250.
27. Modak M., Dixit P., Londhe J., Ghaskadbi S., Paul A.D.T. Indian herbs and herbal drugs used for the treatment of diabetes. J. Clin. Biochem. Nutr. 2007, 40:163-173.
28. Mukherjee P.K., Maiti K., Mukherjee K., Houghton P.J. Leads from Indian medicinal plants with hypoglycemic potentials. J. Ethnopharmacol. 2006, 106:1-28.
29. Nerurkar P.V., Lee Y.K., Motosue M., Adeli K., Nerurkar V.R. Momordica charantia (bitter melon) reduces plasma apolipoprotein B-100 and increases hepatic insulin receptor substrate and phosphoinositide-3 kinase interactions. Br. J. Nutr. 2008, 100:751-759.
30. Ooi C.P., Yassin Z., Hamid T.A. Momordica charantia for type 2 diabetes mellitus. Cochrane Database Syst. Rev. 2012, 8:CD007845.
31. Patel R., Mahobia N., Upwar N., Waseem N., Talaviya H., Patel Z. Analgesic and antipyretic activities of Momordica charantia Linn. fruits. J. Adv. Pharm. Technol. Res. 2010, 4:415-418.
32. Raman A., Lau C. Anti-diabetic properties and phytochemistry of Momordica charantia L. (Cucurbitaceae). Phytomedicine 1996, 2:349-362.
33. Rathi S.S., Grover J.K., Vats V. The effect of Momordica charantia and Mucuna pruriens in experimental diabetes and their effect on key metabolic enzymes involved in carbohydrate metabolism. Phytother. Res. 2002, 16:236-243.
34. Rathi S.S., Grover J.K., Vikrant V., Biswas N.R. Prevention of experimental diabetic cataract by Indian Ayurvedic plant extracts. Phytother. Res. 2002, 16:774-777.
35. Reaven G.M. Insulin resistance may or may not play a role in blood pressure regulation. J. Intern. Med. 1998, 244:359-360.
36. Robertson R.P. Chronic oxidative stress as a central mechanism for glucose toxicity in pancreatic islet beta cells in diabetes. J. Biol. Chem. 2004, 279:42351-42354.
37. Robertson R.P., Harmon J., Tran P.O., Poitout V. Beta-cell glucose toxicity, lipotoxicity, and chronic oxidative stress in type 2 diabetes. Diabetes 2004, 53(Suppl. 1):S119-124.
38. Sarkar S., Pranava M., Marita R. Demonstration of the hypoglycemic action of Momordica charantia in a validated animal model of diabetes. Pharmacol. Res. 1996, 33:1-4.
39. Schrauwen P., Lichtenbelt W.D., Saris W.H., Westerterp K.R. Fat balance in obese subjects: role of glycogen stores. Am. J. Physiol. 1998, 274:E1027-E1033.
40. Shibib B.A., Khan L.A., Rahman R. Hypoglycaemic activity of Coccinia indica and Momordica charantia in diabetic rats: depression of the hepatic gluconeogenic enzymes glucose-6-phosphatase and fructose-1,6-bisphosphatase and elevation of both liver and red-cell shunt enzyme glucose-6-phosphate dehydrogenase. Biochem. J. 1993, 292(Pt 1):267-270.
41. Shih C.C., Lin C.H., Lin W.L. Effects of Momordica charantia on insulin resistance and visceral obesity in mice on high-fat diet. Diabetes Res. Clin. Pract. 2008, 81:134-143.
42. Shih C.C., Lin C.H., Lin W.L., Wu J.B. Momordica charantia extract on insulin resistance and the skeletal muscle GLUT4 protein in fructose-fed rats. J. Ethnopharmacol. 2009, 123:82-90.
43. Shimizu R., Sakazaki F., Okuno T., Nakamuro K., Ueno H. Difference in glucose intolerance between C57BL/6J and ICR strain mice with streptozotocin/nicotinamide-induced diabetes. Biomed. Res. 2012, 33:63-66.
44. Shiota A., Shimabukuro M., Fukuda D., Soeki T., Sato H., Uematsu E., Hirata Y., Kurobe H., Sakaue H., Nakaya Y., Masuzaki H., Sata M. Activation of AMPK-Sirt1 pathway by telmisartan in white adipose tissue: a possible link to anti-metabolic effects. Eur. J. Pharmacol. 2012, 692:84-90.
45. Silva N., Atlantis E., Ismail K. A review of the association between depression and insulin resistance. Pitfalls of secondary analyses or a promising new approach to prevention of type 2 diabetes?. Curr. Psychiatry Rep. 2012, 14:8-14.
46. Singh N., Gupta M., Sirohi P., Varsha Effects of alcoholic extract of Momordica charantia (Linn.) whole fruit powder on the pancreatic islets of alloxan diabetic albino rats. J. Environ. Biol. 2008, 29:101-106.
47. Sitasawad S.L., Shewade Y., Bhonde R. Role of bittergourd fruit juice in stz-induced diabetic state in vivo and in vitro. J. Ethnopharmacol. 2000, 73:71-79.
48. Sundaram E.N., Reddy P.U., Singh K.P. Effect of alcoholic extracts of Indian medicinal plants on the altered enzymatic activities of diabetic rats. Indian J. Pharm. Sci. 2009, 71:594-598.
49. Tahara A., Matsuyama-Yokono A., Shibasaki M. Effects of antidiabetic drugs in high-fat diet and streptozotocin-nicotinamide-induced type 2 diabetic mice. Eur. J. Pharmacol. 2011, 655:108-116.
50. Vikrant V., Grover J.K., Tandon N., Rathi S.S., Gupta N. Treatment with extracts of Momordica charantia and Eugenia jambolana prevents hyperglycemia and hyperinsulinemia in fructose fed rats. J. Ethnopharmacol. 2001, 76(2):139-143.
51. Wang Z.Q., Zhang X.H., Yu Y., Poulev A., Ribnicky D., Floyd Z.E., Cefalu W.T. Bioactives from bitter melon enhance insulin signaling and modulate acyl carnitine content in skeletal muscle in high-fat diet-fed mice. J. Nutr. Biochem. 2011, 22:1064-1073.
52. Yeh G.Y., Eisenberg D.M., Kaptchuk T.J., Phillips R.S. Systematic review of herbs and dietary supplements for glycemic control in diabetes. Diabetes Care 2003, 26:1277-1294.
53. Zhang X., Sun N., Wang L., Guo H., Guan Q., Cui B., Tian L., Gao L., Zhao J. AMP-activated protein kinase and pancreatic/duodenal homeobox-1 involved in insulin secretion under high leucine exposure in rat insulinoma beta-cells. J. Cell Mol. Med. 2009, 13:758-770.